Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,455 signal articles · 146 in last 24h · 154,143 total before filter · latest 1h ago
146last 24h
877last 7d
147● bullish (7d)
96● bearish (7d)
214publishers
AllMacro211Earnings108M&A126Regulatory21Product21Analyst17
✕ clear all filtersticker: ^GSPCSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
2 Reasons to Like SXI (and 1 Not So Much)
StockStory9h agoneutral
2 Reasons to Like SXI (and 1 Not So Much)

While the S&P 500 is up 18.4% since March 2026, Standex (currently trading at $275.55 per share) has lagged behind, posting a return of 6%. This may have investors wondering how to approach the situation.

3 Reasons to Avoid SHW and 1 Stock to Buy Instead
StockStory9h agobullish
3 Reasons to Avoid SHW and 1 Stock to Buy Instead

Sherwin-Williams currently trades at $326.33 per share and has shown little upside over the past six months, posting a middling return of 4%. The stock also fell short of the S&P 500’s 18.4% gain during that period.

3 Reasons to Avoid AMPH and 1 Stock to Buy Instead
StockStory10h agobullish
3 Reasons to Avoid AMPH and 1 Stock to Buy Instead

Over the past six months, Amphastar Pharmaceuticals has been a great trade, beating the S&P 500 by 11.4%. Its stock price has climbed to $24.97, representing a healthy 29.8% increase. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

3 Reasons MYGN is Risky and 1 Stock to Buy Instead
StockStory10h agobullish
3 Reasons MYGN is Risky and 1 Stock to Buy Instead

Over the past six months, Myriad Genetics’s stock price fell to $4.01. Shareholders have lost 13% of their capital, which is disappointing considering the S&P 500 has climbed by 18.4%. This was partly due to its softer quarterly results and might have investors contemplating their next move.

2 Reasons to Like WHD and 1 to Stay Skeptical
StockStory10h agoneutral
2 Reasons to Like WHD and 1 to Stay Skeptical

Cactus has had an impressive run over the past six months as its shares have beaten the S&P 500 by 18.3%. The stock now trades at $66.05, marking a 36.7% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

2 Reasons to Like CRC and 1 to Stay Skeptical
StockStory10h agoneutral
2 Reasons to Like CRC and 1 to Stay Skeptical

Over the past six months, California Resources’s stock price fell to $53.17. Shareholders have lost 18.6% of their capital, which is disappointing considering the S&P 500 has climbed by 18.4%. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.

3 Reasons to Sell GEL and 1 Stock to Buy Instead
StockStory10h agoneutral
3 Reasons to Sell GEL and 1 Stock to Buy Instead

Over the past six months, Genesis Energy’s shares (currently trading at $14.67) have posted a disappointing 18.2% loss, well below the S&P 500’s 18.4% gain. This may have investors wondering how to approach the situation.

Why Historic Yields Aren't Hitting Stocks Even Harder
Barrons.com10h agoneutral
Why Historic Yields Aren't Hitting Stocks Even Harder

Stocks were in the red on Thursday, but the losses weren't that severe considering the scale of the bond market weakness. The S&P 500 was down 0.2% to 7693.66, just 1.4% from its record high closing price, according to Dow Jones Market Data. The Nasdaq Composite dropped 0.5%, trading only 1.6% from its respective high.

Bloom Energy Corporation (BE): A Critical Player in AI Buildout
Insider Monkey11h agoneutral
Bloom Energy Corporation (BE): A Critical Player in AI Buildout

Tran Capital Management, an investment management company, released its second-quarter investor letter for its “Midcap Equity Strategy”. The letter can be downloaded here. The Midcap Equity Strategy returned 16.9%, net of fees, in the second quarter, bringing year-to-date returns to 12.3%, compared with Bloomberg U.S. Mid Cap Index’s 11.1% quarterly gains and 12.1% year-to-date returns. […]

Taiwan Semiconductor (TSM): The Key Enabler of AI Chips and a Durable Long-Term Share Gainer
Insider Monkey11h agoneutral
Taiwan Semiconductor (TSM): The Key Enabler of AI Chips and a Durable Long-Term Share Gainer

Tran Capital Management, an investment management company, released its second-quarter investor letter for its “Multi Cap Growth Strategy”. You can download a copy of the letter here. In Q2, the Strategy returned 17.5% net (YTD 10.5%), outperforming the S&P 500 (15.2%) and Bloomberg U.S. Mid Cap Index (11.1%). Patient discipline during Q1’s sell-off drove these […]

Palo Alto Networks (PANW) is Strengthening from Enterprise Security Consolidation Amid Rising AI Threats
Insider Monkey11h agoneutral
Palo Alto Networks (PANW) is Strengthening from Enterprise Security Consolidation Amid Rising AI Threats

Tran Capital Management, an investment management company, released its second-quarter investor letter for its “Multi Cap Growth Strategy”. You can download a copy of the letter here. In Q2, the Strategy returned 17.5% net (YTD 10.5%), outperforming the S&P 500 (15.2%) and Bloomberg U.S. Mid Cap Index (11.1%). Patient discipline during Q1’s sell-off drove these […]

2 Reasons to Like CL (and 1 Not So Much)
StockStory11h agoneutral
2 Reasons to Like CL (and 1 Not So Much)

Colgate-Palmolive currently trades at $86.14 per share and has shown little upside over the past six months, posting a middling return of 1.9%. The stock also fell short of the S&P 500’s 18.4% gain during that period.

CBRE (CBRE): Buy, Sell, or Hold Post Q2 Earnings?
StockStory11h agoneutral
CBRE (CBRE): Buy, Sell, or Hold Post Q2 Earnings?

CBRE has been treading water for the past six months, recording a small return of 2.6% while holding steady at $136.36. The stock also fell short of the S&P 500’s 18.4% gain during that period.